Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 156
Filtrar
1.
Res Sq ; 2024 Aug 26.
Artículo en Inglés | MEDLINE | ID: mdl-39257974

RESUMEN

Acute myeloid leukemia (AML) is the most prevalent type of leukemia in adults. Its heterogeneity, both between patients and within the same patient, is often a factor contributing to poor treatment outcomes. Despite advancements in AML biology and medicine in general, the standard AML treatment, the combination of cytarabine and daunorubicin, has remained the same for decades. Combination drug therapies are proven effective in achieving targeted efficacy while minimizing drug dosage and unintended side effects, a common problem for older AML patients. However, a systematic survey of the synergistic potential of drug-drug interactions in the context of AML pathology is lacking. Here, we examine the interactions between 15 commonly used cancer drugs across distinct AML cell lines and demonstrate that synergistic and antagonistic drug-drug interactions are widespread but not conserved across these cell lines. Notably, enasidenib and venetoclax, recently approved anticancer agents, exhibited the highest counts of synergistic interactions and the fewest antagonistic ones. In contrast, 6-Thioguanine, a purine analog, was involved in the highest number of antagonistic interactions. The interactions we report here cannot be attributed solely to the inherent natures of these three drugs, as each drug we examined was involved in several synergistic or antagonistic interactions in the cell lines we tested. Importantly, these drug-drug interactions are not conserved across cell lines, suggesting that the success of combination therapies might vary significantly depending on AML genotypes. For instance, we found that a single mutation in the TF1 cell line could dramatically alter drug-drug interactions, even turning synergistic interactions into antagonistic ones. Our findings provide a preclinical survey of drug-drug interactions, revealing the complexity of the problem.

2.
Eur J Surg Oncol ; 49(8): 1504-1510, 2023 08.
Artículo en Inglés | MEDLINE | ID: mdl-36958949

RESUMEN

OBJECTIVE: To investigate decision making for patients with advanced ovarian cancer as a possible explanation of geographical variation in treatment patterns. METHODS: We carried out a multi-centre observational study in multidisciplinary teams meetings for five major UK cancer centres. All patients presenting to five cancer centres with advanced ovarian cancer over a six-week period. The GO-MDT-MODe tool was used to provide a measure of participation and quality of case discussion for all cases of advanced ovarian cancer. MDT scores were correlated with surgical data extracted from national audit data. Data were recorded for overall MDT performance. RESULTS: A total of 870 case discussions, including 145 cases of advanced ovarian cancer, were observed. MDTs varied in structure, format and time allocation between centres. Cluster analysis showed significant variation in quality and participation of discussion between centres (p < 0.0025) and this correlated with the proportion of patients in the wider cancer alliance undergoing surgery. CONCLUSIONS: We have shown that at least part of the variation in practice seen in the UK correlates with different behaviours within MDTs. Increasing time for discussion and encouraging participation from all staff groups may increase proportions of patients undergoing optimal treatment regimens.


Asunto(s)
Neoplasias de los Genitales Masculinos , Neoplasias Ováricas , Masculino , Humanos , Femenino , Grupo de Atención al Paciente , Carcinoma Epitelial de Ovario , Neoplasias Ováricas/cirugía
3.
Am J Physiol Heart Circ Physiol ; 324(2): H198-H209, 2023 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-36525480

RESUMEN

During ischemic heart failure (IHF), cardiac muscle contraction is typically impaired, though the molecular changes within the myocardium are not fully understood. Thus, we aimed to characterize the biophysical properties of cardiac myosin in IHF. Cardiac tissue was harvested from 10 age-matched males, either with a history of IHF or nonfailing (NF) controls that had no history of structural or functional cardiac abnormalities. Clinical measures before cardiac biopsy demonstrated significant differences in measures of ejection fraction and left ventricular dimensions. Myofibrils and myosin were extracted from left ventricular free wall cardiac samples. There were no changes in myofibrillar ATPase activity or calcium sensitivity between groups. Using isolated myosin, we found a 15% reduction in the IHF group in actin sliding velocity in the in vitro motility assay, which was observed in the absence of a myosin isoform shift. Oxidative damage (carbonylation) of isolated myosin was compared, in which there were no significant differences between groups. Synthetic thick filaments were formed from purified myosin and the ATPase activity was similar in both basal and actin-activated conditions (20 µM actin). Correlation analysis and Deming linear regression were performed between all studied parameters, in which we found statistically significant correlations between clinical measures of contractility with molecular measures of sliding velocity and ELC carbonylation. Our data indicate that subtle deficits in myosin mechanochemical properties are associated with reduced contractile function and pathological remodeling of the heart, suggesting that the myosin motor may be an effective pharmacological intervention in ischemia.NEW & NOTEWORTHY Ischemic heart failure is associated with impairments in contractile performance of the heart. This study revealed that cardiac myosin isolated from patients with ischemic heart failure had reduced mechanical activity, which correlated with the impaired clinical phenotype of the patients. The results suggest that restoring myosin function with pharmacological intervention may be a viable method for therapeutic intervention.


Asunto(s)
Insuficiencia Cardíaca , Disfunción Ventricular Izquierda , Masculino , Humanos , Actinas , Miosinas Cardíacas , Miocardio , Miosinas , Miofibrillas , Contracción Miocárdica
4.
Yeast ; 37(3): 269-279, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-31960994

RESUMEN

In Saccharomyces cerevisiae under conditions of nutrient stress, meiosis precedes the formation of spores. Although the molecular mechanisms that regulate meiosis, such as meiotic recombination and nuclear divisions, have been extensively studied, the metabolic factors that determine the efficiency of sporulation are less understood. Here, we have directly assessed the relationship between metabolic stores and sporulation in S. cerevisiae by genetically disrupting the synthetic pathways for the carbohydrate stores, glycogen (gsy1/2Δ cells), trehalose (tps1Δ cells), or both (gsy1/2Δ and tps1Δ cells). We show that storage carbohydrate-deficient strains are highly inefficient in sporulation. Although glycogen and trehalose stores can partially compensate for each other, they have differential effects on sporulation rate and spore number. Interestingly, deletion of the G1 cyclin, CLN3, which resulted in an increase in cell size, mitochondria and lipid stores, partially rescued meiosis progression and spore ascus formation but not spore number in storage carbohydrate-deficient strains. Sporulation efficiency in the carbohydrate-deficient strain exhibited a greater dependency on mitochondrial activity and lipid stores than wild-type yeast. Taken together, our results provide new insights into the complex crosstalk between metabolic factors that support gametogenesis.


Asunto(s)
Carbohidratos/química , Lípidos/química , Saccharomyces cerevisiae/metabolismo , Esporas Fúngicas/fisiología , Ciclinas/genética , Ciclinas/metabolismo , Replicación del ADN , Regulación Fúngica de la Expresión Génica , Meiosis , Mitocondrias/metabolismo , Proteínas de Saccharomyces cerevisiae/genética , Proteínas de Saccharomyces cerevisiae/metabolismo , Transcriptoma
6.
BJOG ; 124(1): 150-160, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27062690

RESUMEN

OBJECTIVE: To evaluate the effectiveness of nurse-led telephone follow-up (TFU) for patients with stage-I endometrial cancer. DESIGN: Multicentre, randomised, non-inferiority trial. SETTING: Five centres in the North West of England. SAMPLE: A cohort of 259 women treated for stage-I endometrial cancer attending hospital outpatient clinics for routine follow-up. METHODS: Participants were randomly allocated to receive traditional hospital based follow-up (HFU) or nurse-led TFU. MAIN OUTCOME MEASURES: Primary outcomes were psychological morbidity (State Trait Anxiety Inventory, STAI-S) and patient satisfaction with the information provided. Secondary outcomes included patient satisfaction with service, quality of life, and time to detection of recurrence. RESULTS: The STAI-S scores post-randomisation were similar between groups [mean (SD): TFU 33.0 (11.0); HFU 35.5 (13.0)]. The estimated between-group difference in STAI-S was 0.7 (95% confidence interval, 95% CI -1.9 to 3.3); the confidence interval lies above the non-inferiority limit (-3.5), indicating the non-inferiority of TFU. There was no significant difference between groups in reported satisfaction with information (odds ratio, OR 0.9; 95% CI 0.4-2.1; P = 0.83). Women in the HFU group were more likely to report being kept waiting for their appointment (P = 0.001), that they did not need any information (P = 0.003), and were less likely to report that the nurse knew about their particular case and situation (P = 0.005). CONCLUSIONS: The TFU provides an effective alternative to HFU for patients with stage-I endometrial cancer, with no reported physical or psychological detriment. Patient satisfaction with information was high, with similar levels between groups. TWEETABLE ABSTRACT: ENDCAT trial shows effectiveness of nurse-led telephone follow-up for patients with stage-I endometrial cancer.


Asunto(s)
Neoplasias Endometriales/enfermería , Rol de la Enfermera , Servicio Ambulatorio en Hospital , Pacientes Ambulatorios , Satisfacción del Paciente , Calidad de Vida , Teléfono , Neoplasias Endometriales/epidemiología , Inglaterra/epidemiología , Femenino , Estudios de Seguimiento , Humanos , Estadificación de Neoplasias , Pacientes Ambulatorios/estadística & datos numéricos , Teléfono/estadística & datos numéricos , Recursos Humanos
7.
Neurobiol Aging ; 48: 222.e1-222.e7, 2016 12.
Artículo en Inglés | MEDLINE | ID: mdl-27640074

RESUMEN

A shared genetic susceptibility between cutaneous malignant melanoma (CMM) and Parkinson's disease (PD) has been suggested. We investigated this by assessing the contribution of rare variants in genes involved in CMM to PD risk. We studied rare variation across 29 CMM risk genes using high-quality genotype data in 6875 PD cases and 6065 controls and sought to replicate findings using whole-exome sequencing data from a second independent cohort totaling 1255 PD cases and 473 controls. No statistically significant enrichment of rare variants across all genes, per gene, or for any individual variant was detected in either cohort. There were nonsignificant trends toward different carrier frequencies between PD cases and controls, under different inheritance models, in the following CMM risk genes: BAP1, DCC, ERBB4, KIT, MAPK2, MITF, PTEN, and TP53. The very rare TYR p.V275F variant, which is a pathogenic allele for recessive albinism, was more common in PD cases than controls in 3 independent cohorts. Tyrosinase, encoded by TYR, is the rate-limiting enzyme for the production of neuromelanin, and has a role in the production of dopamine. These results suggest a possible role for another gene in the dopamine-biosynthetic pathway in susceptibility to neurodegenerative Parkinsonism, but further studies in larger PD cohorts are needed to accurately determine the role of these genes/variants in disease pathogenesis.


Asunto(s)
Estudios de Asociación Genética , Predisposición Genética a la Enfermedad/genética , Variación Genética/genética , Melanoma/genética , Enfermedad de Parkinson/genética , Neoplasias Cutáneas/genética , Estudios de Cohortes , Receptor DCC , Dopamina/biosíntesis , Genotipo , Humanos , Melaninas/biosíntesis , Glicoproteínas de Membrana/genética , Monofenol Monooxigenasa , Oxidorreductasas/genética , Pigmentación/genética , Receptor ErbB-4/genética , Receptores de Superficie Celular/genética , Riesgo , Proteínas Supresoras de Tumor/genética , Ubiquitina Tiolesterasa/genética
8.
BJOG ; 123(13): 2171-2180, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27006076

RESUMEN

OBJECTIVE: To explore the impact of risk-adjustment on surgical complication rates (CRs) for benchmarking gynaecological oncology centres. DESIGN: Prospective cohort study. SETTING: Ten UK accredited gynaecological oncology centres. POPULATION: Women undergoing major surgery on a gynaecological oncology operating list. METHODS: Patient co-morbidity, surgical procedures and intra-operative (IntraOp) complications were recorded contemporaneously by surgeons for 2948 major surgical procedures. Postoperative (PostOp) complications were collected from hospitals and patients. Risk-prediction models for IntraOp and PostOp complications were created using penalised (lasso) logistic regression using over 30 potential patient/surgical risk factors. MAIN OUTCOME MEASURES: Observed and risk-adjusted IntraOp and PostOp CRs for individual hospitals were calculated. Benchmarking using colour-coded funnel plots and observed-to-expected ratios was undertaken. RESULTS: Overall, IntraOp CR was 4.7% (95% CI 4.0-5.6) and PostOp CR was 25.7% (95% CI 23.7-28.2). The observed CRs for all hospitals were under the upper 95% control limit for both IntraOp and PostOp funnel plots. Risk-adjustment and use of observed-to-expected ratio resulted in one hospital moving to the >95-98% CI (red) band for IntraOp CRs. Use of only hospital-reported data for PostOp CRs would have resulted in one hospital being unfairly allocated to the red band. There was little concordance between IntraOp and PostOp CRs. CONCLUSION: The funnel plots and overall IntraOp (≈5%) and PostOp (≈26%) CRs could be used for benchmarking gynaecological oncology centres. Hospital benchmarking using risk-adjusted CRs allows fairer institutional comparison. IntraOp and PostOp CRs are best assessed separately. As hospital under-reporting is common for postoperative complications, use of patient-reported outcomes is important. TWEETABLE ABSTRACT: Risk-adjusted benchmarking of surgical complications for ten UK gynaecological oncology centres allows fairer comparison.


Asunto(s)
Benchmarking/métodos , Neoplasias de los Genitales Femeninos , Procedimientos Quirúrgicos Ginecológicos/efectos adversos , Complicaciones Posoperatorias , Adulto , Anciano , Estudios de Cohortes , Comorbilidad , Femenino , Neoplasias de los Genitales Femeninos/epidemiología , Neoplasias de los Genitales Femeninos/cirugía , Procedimientos Quirúrgicos Ginecológicos/métodos , Procedimientos Quirúrgicos Ginecológicos/estadística & datos numéricos , Humanos , Persona de Mediana Edad , Evaluación de Resultado en la Atención de Salud/métodos , Evaluación de Resultado en la Atención de Salud/estadística & datos numéricos , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/etiología , Prevalencia , Estudios Prospectivos , Ajuste de Riesgo/métodos , Ajuste de Riesgo/estadística & datos numéricos , Medición de Riesgo/métodos , Factores de Riesgo , Reino Unido/epidemiología
9.
Acta Neurol Scand ; 134(4): 271-6, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26626018

RESUMEN

BACKGROUND: Parkin related Parkinson's disease (PD) is differentiated from idiopathic PD by absent or sparse Lewy bodies, and preserved olfaction. The significance of single Parkin mutations in the pathogenesis of PD is debated. OBJECTIVES: To assess olfaction results according to Parkin mutation status. To compare the prevalence of Parkin single heterozygous mutations in patients diagnosed with PD to the rate in healthy controls in order to establish whether these single mutations could be a risk factor for developing PD. METHODS: Parkin gene mutation testing was performed in young onset PD (diagnosed <50 years old) to identify three groups: Parkin homozygous or compound heterozygote mutation carriers, Parkin single heterozygote mutation carriers, and non-carriers of Parkin mutations. Olfaction was tested using the 40-item British version of the University of Pennsylvania smell identification test (UPSIT). RESULTS: Of 344 young onset PD cases tested, 8 (2.3%) were Parkin compound heterozygotes and 13 (3.8%) were Parkin single heterozygotes. Olfaction results were available in 282 cases (eight compound heterozygotes, nine single heterozygotes, and 265 non-carriers). In Parkin compound heterozygotes, the median UPSIT score was 33, interquartile range (IQR) 28.5-36.5, which was significantly better than in single Parkin heterozygotes (median 19, IQR 18-28) and non-carriers (median score 22, IQR 16-28) (ANOVA P < 0.001). These differences persisted after adjusting for age, disease duration, gender, and smoking (P < 0.001). There was no significant difference in UPSIT scores between single heterozygotes and non-carriers (P = 0.90). CONCLUSIONS: Patients with Parkin compound heterozygous mutations have relatively preserved olfaction compared to Parkin single heterozygotes and non-carriers. The prevalence of Parkin single heterozygosity is similar to the 3.7% rate reported in healthy controls.


Asunto(s)
Enfermedad de Parkinson/genética , Enfermedad de Parkinson/psicología , Olfato/genética , Ubiquitina-Proteína Ligasas/genética , Adulto , Edad de Inicio , Anciano , Trastornos del Conocimiento/epidemiología , Trastornos del Conocimiento/etiología , Trastornos del Conocimiento/genética , Estudios de Cohortes , ADN/genética , Femenino , Frecuencia de los Genes , Genotipo , Heterocigoto , Humanos , Masculino , Persona de Mediana Edad , Mutación/genética , Pruebas Neuropsicológicas , Enfermedad de Parkinson/epidemiología , Prevalencia
10.
BJOG ; 122(5): 615-22, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25559096

RESUMEN

BACKGROUND: Patient-reported outcome measures (PROMs) are used to assess the impact of health care on a patient's health. Within the gynaecological oncology setting, multiple PROMs have been adopted but no assessment has been made in terms of their psychometric qualities and robustness. OBJECTIVES: To undertake a systematic review to identify the most psychometrically robust and appropriate PROM used in the gynaecological oncology setting. SEARCH STRATEGY: A search of the bibliographic database of the Oxford PROM group, plus nine additional databases, was carried out along with citation-tracking and hand searches. SELECTION CRITERIA: Studies examining the psychometric properties of outcome measures tested in gynaecological cancer populations were selected by three blinded reviewers. DATA COLLECTION AND ANALYSIS: Studies were independently assessed and data extracted. Analysis included an appraisal of the psychometric properties and functionality of the included PROMs to guide recommendations. MAIN RESULTS: Eighteen PROMs tested in gynaecological oncology settings were identified. These were categorised into seven areas of focus, and the most psychometrically robust tools were identified: (1) generic (no recommendation); (2) general cancer (EORTC QLQ-C30 and FACT-G); (3) pelvic cancer (QUEST GY); (4) ovarian cancer (EORTC QLQ-OV28); (5) cervical cancer (EORTC QLQ-CX24); (6) endometrial cancer (EORTC QLQ-EN 24); and (7) vulval cancer (FACT-V). AUTHOR'S CONCLUSIONS: Seven PROMs were recommended for use in six gynaecological populations. No single tool was identified that had been tested in all disease groups. Some showed promise, but a lack of conceptual clarity about the core outcomes and the rationale for use will require further testing using well-constructed studies.


Asunto(s)
Prestación Integrada de Atención de Salud/normas , Neoplasias de los Genitales Femeninos , Oncología Médica , Evaluación de Resultado en la Atención de Salud , Indicadores de Calidad de la Atención de Salud/normas , Autoinforme/normas , Femenino , Neoplasias de los Genitales Femeninos/psicología , Neoplasias de los Genitales Femeninos/terapia , Humanos , Oncología Médica/métodos , Oncología Médica/organización & administración , Oncología Médica/normas , Oncología Médica/tendencias , Evaluación de Resultado en la Atención de Salud/métodos , Evaluación de Resultado en la Atención de Salud/normas , Psicometría , Reproducibilidad de los Resultados , Encuestas y Cuestionarios/normas , Resultado del Tratamiento
11.
Br J Cancer ; 112(3): 475-84, 2015 Feb 03.
Artículo en Inglés | MEDLINE | ID: mdl-25535730

RESUMEN

BACKGROUND: There are limited data on surgical outcomes in gynaecological oncology. We report on predictors of complications in a multicentre prospective study. METHODS: Data on surgical procedures and resulting complications were contemporaneously recorded on consented patients in 10 participating UK gynaecological cancer centres. Patients were sent follow-up letters to capture any further complications. Post-operative (Post-op) complications were graded (I-V) in increasing severity using the Clavien-Dindo system. Grade I complications were excluded from the analysis. Univariable and multivariable regression was used to identify predictors of complications using all surgery for intra-operative (Intra-op) and only those with both hospital and patient-reported data for Post-op complications. RESULTS: Prospective data were available on 2948 major operations undertaken between April 2010 and February 2012. Median age was 62 years, with 35% obese and 20.4% ASA grade ⩾3. Consultant gynaecological oncologists performed 74.3% of operations. Intra-op complications were reported in 139 of 2948 and Grade II-V Post-op complications in 379 of 1462 surgeries. The predictors of risk were different for Intra-op and Post-op complications. For Intra-op complications, previous abdominal surgery, metabolic/endocrine disorders (excluding diabetes), surgical complexity and final diagnosis were significant in univariable and multivariable regression (P<0.05), with diabetes only in multivariable regression (P=0.006). For Post-op complications, age, comorbidity status, diabetes, surgical approach, duration of surgery, and final diagnosis were significant in both univariable and multivariable regression (P<0.05). CONCLUSIONS: This multicentre prospective audit benchmarks the considerable morbidity associated with gynaecological oncology surgery. There are significant patient and surgical factors that influence this risk.


Asunto(s)
Neoplasias de los Genitales Femeninos/cirugía , Procedimientos Quirúrgicos Ginecológicos/efectos adversos , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/etiología , Anciano , Auditoría Clínica , Femenino , Neoplasias de los Genitales Femeninos/epidemiología , Neoplasias de los Genitales Femeninos/patología , Procedimientos Quirúrgicos Ginecológicos/estadística & datos numéricos , Humanos , Histerectomía/efectos adversos , Histerectomía/estadística & datos numéricos , Escisión del Ganglio Linfático/efectos adversos , Escisión del Ganglio Linfático/estadística & datos numéricos , Persona de Mediana Edad , Complicaciones Posoperatorias/epidemiología , Pronóstico , Estudios Prospectivos , Factores de Riesgo , Resultado del Tratamiento , Reino Unido/epidemiología
12.
SADJ ; 68(6): 278-81, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23971281

RESUMEN

Patients with oculocutaneous albinism are more prone to sun-induced damage due to the lack of melanin. Actinic cheilitis is a potentially malignant disorder that occurs due to chronic UV-B radiation to the vermillion region of the lip, a region that is already at risk due to its morphology. A case of actinic cheilitis in a patient with oculocutaneous albinism is presented with a literature review.


Asunto(s)
Albinismo Oculocutáneo/complicaciones , Queilitis/etiología , Luz Solar/efectos adversos , Queilitis/patología , Diagnóstico Diferencial , Humanos , Masculino , Sudáfrica , Adulto Joven
13.
SADJ ; 68(6): 260, 262-4, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23971278

RESUMEN

It has been reported that a close association exists between inflammatory periodontal diseases and diabetes through which one exerts a reciprocal influence on the other. This two-way relationship is based on the extensively reported assumption that the one condition so modifies the systemic and local environments that the progress of the other is favoured. On the other hand, treating and eliminating inflammatory periodontal diseases results in improved glycaemic control which minimises the microvascular complications of diabetes. This paper provides a brief review in an endeavour to create a better understanding of the interaction between these two relatively common conditions.


Asunto(s)
Periodontitis Crónica/complicaciones , Diabetes Mellitus Tipo 2/complicaciones , Periodontitis Crónica/terapia , Diabetes Mellitus Tipo 2/metabolismo , Dinoprostona/metabolismo , Hemoglobina Glucada/metabolismo , Productos Finales de Glicación Avanzada/metabolismo , Humanos , Resistencia a la Insulina/fisiología , Interleucina-6/metabolismo , Microcirculación , Neutrófilos/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo
14.
Br J Cancer ; 109(3): 623-32, 2013 Aug 06.
Artículo en Inglés | MEDLINE | ID: mdl-23846170

RESUMEN

BACKGROUND: Most studies use hospital data to calculate postoperative complication rates (PCRs). We report on improving PCR estimates through use of patient-reporting. METHODS: A prospective cohort study of major surgery performed at 10 UK gynaecological cancer centres was undertaken. Hospitals entered the data contemporaneously into an online database. Patients were sent follow-up letters to capture postoperative complications. Grade II-V (Clavien-Dindo classification) patient-reported postoperative complications were verified from hospital records. Postoperative complication rate was defined as the proportion of surgeries with a Grade II-V postoperative complication. RESULTS: Patient replies were received for 1462 (68%) of 2152 surgeries undertaken between April 2010 and February 2012. Overall, 452 Grade II-V (402 II, 50 III-V) complications were reported in 379 of the 1462 surgeries. This included 172 surgeries with 200 hospital-reported complications and 231 with 280 patient-reported complications. All (100% concordance) 36 Grade III-V and 158 of 280 (56.4% concordance) Grade II patient-reported complications were verified on hospital case-note review. The PCR using hospital-reported data was 11.8% (172 out of 1462; 95% CI 11-14), patient-reported was 15.8% (231 out of 1462; 95% CI 14-17.8), hospital and verified patient-reported was 19.4% (283 out of 1462; 95% CI 17.4-21.4) and all data were 25.9% (379 out of 1462; 95% CI 24-28). After excluding Grade II complications, the hospital and patient verified Grade III-V PCR was 3.3% (48 out of 1462; 95% CI 2.5-4.3). CONCLUSION: This is the first prospective study of postoperative complications we are aware of in gynaecological oncology to include the patient-reported data. Patient-reporting is invaluable for obtaining complete information on postoperative complications. Primary care case-note review is likely to improve verification rates of patient-reported Grade II complications.


Asunto(s)
Neoplasias de los Genitales Femeninos/cirugía , Procedimientos Quirúrgicos Ginecológicos/efectos adversos , Procedimientos Quirúrgicos Ginecológicos/métodos , Autoinforme , Anciano , Estudios de Cohortes , Femenino , Humanos , Persona de Mediana Edad , Participación del Paciente , Complicaciones Posoperatorias/diagnóstico , Estudios Prospectivos
15.
Cell Death Dis ; 3: e335, 2012 Jun 28.
Artículo en Inglés | MEDLINE | ID: mdl-22739987

RESUMEN

Loss of the mitochondrial protease HtrA2 (Omi) in mice leads to mitochondrial dysfunction, neurodegeneration and premature death, but the mechanism underlying this pathology remains unclear. Using primary cultures from wild-type and HtrA2-knockout mice, we find that HtrA2 deficiency significantly reduces mitochondrial membrane potential in a range of cell types. This depolarisation was found to result from mitochondrial uncoupling, as mitochondrial respiration was increased in HtrA2-deficient cells and respiratory control ratio was dramatically reduced. HtrA2-knockout cells exhibit increased proton translocation through the ATP synthase, in combination with decreased ATP production and truncation of the F1 α-subunit, suggesting the ATP synthase as the source of the proton leak. Uncoupling in the HtrA2-deficient mice is accompanied by altered breathing pattern and, on a cellular level, ATP depletion and vulnerability to chemical ischaemia. We propose that this vulnerability may ultimately cause the neurodegeneration observed in these mice.


Asunto(s)
Adenosina Trifosfato/metabolismo , Potencial de la Membrana Mitocondrial/fisiología , Mitocondrias/metabolismo , Proteínas Mitocondriales/genética , ATPasas de Translocación de Protón/metabolismo , Serina Endopeptidasas/genética , Secuencia de Aminoácidos , Animales , Respiración de la Célula , Serina Peptidasa A2 que Requiere Temperaturas Altas , Ratones , Ratones Noqueados , Proteínas Mitocondriales/metabolismo , Datos de Secuencia Molecular , Fosforilación Oxidativa , Especies Reactivas de Oxígeno/metabolismo , Serina Endopeptidasas/metabolismo
16.
SADJ ; 67(7): 344-7, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23951790

RESUMEN

INTRODUCTION: Leukaemia is a neoplastic dsorder characterized by an excessive proliferation of immature white blood cells and their precursors. Patients with this potentially fatal condition may often first present with gingival enlargement. Early diagnosis of the underlying condition and prompt referral for appropriate therapy, may be life-saving. CASE REPORT: A 27-year-old female was referred to the Department of Oral Medicine and Periodontology complaining of a generalised gingival enlargement that was aesthetically displeasing to her. She insisted on immediate surgical removal of the enlarged gingival tissue but, on counseling, agreed to have prior diagnostic tests performed. A full blood count suggested the presence of an underlying acute myeloid leukaemia. The patient was consequently referred to the Oncology Department for further investigation and management. The diagnosis was confirmed and the subsequent chemotherapeutic intervention was strikingly successful, leading to the complete resolution of the gingival enlargement. CONCLUSION: This paper emphasises the importance of a full diagnostic evaluation of all cases of gingival enlargement and immediate referral should a life-threatening condition be identified, such as, in the present case, acute myeloid leukaemia.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Sobrecrecimiento Gingival/etiología , Leucemia Mieloide Aguda/complicaciones , Adulto , Antibióticos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/administración & dosificación , Citarabina/administración & dosificación , Daunorrubicina/administración & dosificación , Detección Precoz del Cáncer , Femenino , Estudios de Seguimiento , Encía/patología , Hemorragia Gingival/etiología , Sobrecrecimiento Gingival/tratamiento farmacológico , Gingivitis Ulcerosa Necrotizante/etiología , Humanos , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/tratamiento farmacológico , Infiltración Leucémica/complicaciones , Inducción de Remisión
17.
SADJ ; 67(7): 348-52, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23951791

RESUMEN

INTRODUCTION: HIV-associated oral lesions have been used as clinical indicators of HIV infection and/or HIV-disease progression. It is well established that there is a significant reduction in the incidence of most HIV-associated oral lesions in patients on HAART compared with the levels seen in HIV-seropositive patients not on HAART. However, the corollary, namely using the presence of HIV-associated oral lesions as indicators of possible HAART failure, has not been sufficiently studied. METHODS: A literature search done in Pubmed, Ovid, Medline and Biomed Central databases identified as suitable for inclusion in this review four reports, which had considered HIV-associated oral lesions as clinical markers of HAART failure. RESULTS: The practicality of relying on the presence of HIV-associated oral lesions in the prediction of HAART failure was evaluated based on existing literature. Although it was suggested as an option in all four papers reviewed, the use of HIV-associated oral lesions as predictors of HAART failure has been recommended by only one of the studies. CONCLUSION: The use of HIV-associated oral lesions as predictors of HAART failure has been suggested. This has not been studied in the South African, or the African setting.


Asunto(s)
Terapia Antirretroviral Altamente Activa , Infecciones por VIH/tratamiento farmacológico , Enfermedades de la Boca/virología , Recuento de Linfocito CD4 , Predicción , VIH/aislamiento & purificación , Humanos , Insuficiencia del Tratamiento , Carga Viral
18.
SADJ ; 67(8): 448-51, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23951810

RESUMEN

Peripheral odontogenic fibroma is a rare odontogenic neoplasm that occurs on the gingiva, and cases of diffuse gingival involvement are most uncommon. An example of such a case compounded by superimposed plasma cell gingivtis is presented together wth a review of the literature.


Asunto(s)
Neoplasias Gingivales/complicaciones , Gingivitis/complicaciones , Tumores Odontogénicos/complicaciones , Células Plasmáticas/patología , Anciano , Periodontitis Crónica/diagnóstico , Diagnóstico Diferencial , Femenino , Neoplasias Gingivales/diagnóstico , Sobrecrecimiento Gingival/diagnóstico , Gingivitis/diagnóstico , Humanos , Tumores Odontogénicos/diagnóstico
19.
SADJ ; 66(2): 82-5, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21608502

RESUMEN

Human papillomavirus (HPV) is strictly epitheliotropic, infecting stratified squamous cutaneous and mucosal epithelial cells. Oral HPV infection may be subclinical or putatively associated with benign or malignant oral neoplasms. The benign HPV-associated oral lesions, focal epithelial hyperplasia (Heck disease), oral squamous cell papilloma, oral verruca vulgaris (common wart) and oral condyloma acuminatum, are collectively referred to as oral warts. Oral warts are usually asymptomatic, may be persistent or uncommonly, may regress spontaneously. HPV-associated oral warts have a prevalence of 0.5% in the general population, occur in up to 5% of HIV-seropositive subjects, and in up to 23% of HIV-seropositive subjects on highly active antiretroviral therapy. This paper is a clinico-pathological review of HPV-associated oral warts.


Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/virología , Enfermedades de la Boca/etiología , Verrugas/etiología , Infecciones Oportunistas Relacionadas con el SIDA/complicaciones , Infecciones Oportunistas Relacionadas con el SIDA/patología , Hiperplasia Epitelial Focal/etiología , Hiperplasia Epitelial Focal/patología , Hiperplasia Epitelial Focal/virología , Seropositividad para VIH/complicaciones , Humanos , Enfermedades de la Boca/patología , Enfermedades de la Boca/virología , Papiloma/etiología , Papiloma/patología , Verrugas/clasificación , Verrugas/patología
20.
SADJ ; 66(1): 30-2, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21510174

RESUMEN

Bisphosphonates are agents commonly used in the treatment of osteoporosis, and in the management of metastatic bone disease, and of hypercalcaemia of malignancy. Any oral surgical procedure or traumatic event exposing bone to bacterial infection may precipitate osteonecrosis of the jaw in subjects who have been treated with bisphosphonates which suppress bone turnover and inhibit the angiogenesis associated with healing. New guidelines for the treatment of bisphosphonate-related osteonecrosis of the jaw are emerging, but hitherto treatment has been empirically conservative.


Asunto(s)
Conservadores de la Densidad Ósea/efectos adversos , Difosfonatos/efectos adversos , Enfermedades Maxilomandibulares/inducido químicamente , Osteonecrosis/inducido químicamente , Remodelación Ósea/efectos de los fármacos , Humanos , Enfermedades Maxilomandibulares/terapia , Neovascularización Fisiológica/efectos de los fármacos , Osteonecrosis/terapia , Factores de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA